An Open-label Study Evaluating Pharmacokinetics, Efficacy, Safety, and Tolerability of CABENUVA IM Administered Monthly and Every 2 months in Virologically Suppressed HIV-Infected Adults having Severe Renal Impairment With or Without Hemodi